Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)


Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.

Aim(s): To assess the potential prognostic impact of MET administered during EVE therapy among DM pts with advanced NETs.

Materials and methods: We retrospectively identified pts with advanced G1-G2 gastroenteropancreatic and lung NETs treated with EVE at 7 Spanish University hospitals. Cox proportional hazard models controlling for primary tumour site, grade and previous therapies were used to compare progression-free survival (PFS) across non-DM pts, DM pts on MET and DM pts on anti-DM agents other than MET.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Custodio A

Authors: Custodio A, Jiménez-Fonseca P, Alonso-Orduña V, López López C, Alonso T,

Keywords: NET, diabetes, metformin, everolimus,

To read the full abstract, please log into your ENETS Member account.